Ligand-dependent disorder of the Ω loop observed in extended-spectrum SHV-type β-lactamase

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 5, 2011, Pages 2303-2309

  Sampson, Jared M ^a   Ke, Wei ^a   Bethel, Christopher R ^b   Pagadala, S R R ^c   Nottingham, Michael D ^c   Bonomo, Robert A ^a,b   Buynak, John D ^c   Van Den Akker, Focco ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^c SOUTHERN METHODIST UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE INHIBITOR; BETA LACTAMASE SHV; EXTENDED SPECTRUM BETA LACTAMASE; TAZOBACTAM;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; CRYSTAL STRUCTURE; ENZYME ACTIVE SITE; ENZYME INACTIVATION; NONHUMAN; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; ESCHERICHIA COLI; MOLECULAR STRUCTURE; MUTAGENESIS, SITE-DIRECTED; PENICILLANIC ACID; X-RAY DIFFRACTION;

EID: 79955549899     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01360-10     Document Type: Article

References (27)

1. Arlet, G., M. Rouveau, and A. Philippon. 1997. Substitution of alanine for aspartate at position 179 in the SHV-6 extended-spectrum β-lactamase. FEMS Microbiol. Lett. 152:163-167.
2. Babic, M., A. M. Hujer, and R. A. Bonomo. 2006. What's new in antibiotic resistance? Focus on β-lactamases. Drug Resist. Updat. 9:142-156.
3. Bonomo, R. A., S. D. Rudin, and D. M. Shlaes. 1997. OHIO-1 β-lactamase mutants: Asp179Gly mutation confers resistance to ceftazidime. FEMS Microbiol. Lett. 152:275-278.
4. Bush, K., and G. Jacoby. 2003. Resistant TEM and SHV β-lactamases. The Lahey Clinic, Burlington, MA. http://www.lahey.org/studies/.
5. Crichlow, G. V., et al. 1999. Structure of the extended-spectrum class C β-lactamase of Enterobacter cloacae GC1, a natural mutant with a tandem tripeptide insertion. Biochemistry 38:10256-10261.
6. De Champs, C., et al. 2004. Frequency and diversity of class A extended-spectrum β-lactamases in hospitals of the Auvergne, France: a 2 year prospective study. J. Antimicrob. Chemother. 54:634-639.
7. Delmas, J., et al. 2010. Structural insights into substrate recognition and product expulsion in CTX-M enzymes. J. Mol. Biol. 400:108-120.
8. Emsley, P., and K. Cowtan. 2004. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60:2126-2132.
9. Fisher, J. F., S. O. Meroueh, and S. Mobashery. 2005. Bacterial resistance to β-lactam antibiotics: compelling opportunism, compelling opportunity. Chem. Rev. 105:395-424.
10. Giakkoupi, P., E. Tzelepi, P. T. Tassios, N. J. Legakis, and L. S. Tzouvelekis. 2000. Detrimental effect of the combination of R164S with G238S in TEM-1 β-lactamase on the extended-spectrum activity conferred by each single mutation. J. Antimicrob. Chemother. 45:101-104.
11. Helfand, M. S., et al. 2003. Understanding resistance to β-lactams and β-lactamase inhibitors in the SHV β-lactamase: lessons from the mutagenesis of Ser130. J. Biol. Chem. 278:52724-52729.
12. Helfand, M. S., A. M. Hujer, F. D. Sonnichsen, and R. A. Bonomo. 2002. Unexpected advanced generation cephalosporinase activity of the M69F variant of SHV β-lactamase. J. Biol. Chem. 277:47719-47723.
13. Herzberg, O., G. Kapadia, B. Blanco, T. S. Smith, and A. Coulson. 1991. Structural basis for the inactivation of the P54 mutant of β-lactamase from Staphylococcus aureus PC1. Biochemistry 30:9503-9509.
14. Hujer, A. M., K. M. Hujer, and R. A. Bonomo. 2001. Mutagenesis of amino acid residues in the SHV-1 β-lactamase: the premier role of Gly238Ser in penicillin and cephalosporin resistance. Biochim. Biophys. Acta 1547:37-50.
15. Kurokawa, H., et al. 2000. A new SHV-derived extended-spectrum β-lactamase (SHV-24) that hydrolyzes ceftazidime through a single-amino-acid substitution (D179G) in the omega-loop. Antimicrob. Agents Chemother. 44:1725-1727.
16. Kuzin, A. P., et al. 1999. Structure of the SHV-1 β-lactamase. Biochemistry 38:5720-5727.
17. Majiduddin, F. K., and T. Palzkill. 2003. An analysis of why highly similar enzymes evolve differently. Genetics 163:457-466. (Pubitemid 36314529)
18. Matagne, A., J. Lamotte-Brasseur, and J. M. Frere. 1998. Catalytic properties of class A β-lactamases: efficiency and diversity. Biochem. J. 330(Pt. 2):581-598.
19. Nukaga, M., et al. 2003. Inhibition of class A and class C β-lactamases by penems: crystallographic structures of a novel 1,4-thiazepine intermediate. Biochemistry 42:13152-13159. (Pubitemid 37420667)
20. Otwinowski, Z., and W. Minor. 1997. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276:307-326. (Pubitemid 27085611)
21. Padayatti, P. S., et al. 2004. Tazobactam forms a stoichiometric trans-enamine intermediate in the E166A variant of SHV-1 β-lactamase: 1.63 Å crystal structure. Biochemistry 43:843-848. (Pubitemid 38141480)
22. Padayatti, P. S., et al. 2006. Rational design of a β-lactamase inhibitor achieved via stabilization of the trans-enamine intermediate: 1.28 A crystal structure of wt SHV-1 complex with a penam sulfone. J. Am. Chem. Soc. 128:13235-13242.
23. Paterson, D. L., and R. A. Bonomo. 2005. Extended-spectrum β-lactamases: a clinical update. Clin. Microbiol. Rev. 18:657-686.
24. Rasheed, J. K., et al. 1997. Evolution of extended-spectrum β-lactam resistance (SHV-8) in a strain of Escherichia coli during multiple episodes of bacteremia. Antimicrob. Agents Chemother. 41:647-653.
25. Schuttelkopf, A. W., and D. M. van Aalten. 2004. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr. D Biol. Crystallogr. 60:1355-1363.
26. Wang, X., G. Minasov, and B. K. Shoichet. 2002. Evolution of an antibiotic resistance enzyme constrained by stability and activity trade-offs. J. Mol. Biol. 320:85-95.
27. Winn, M. D., G. N. Murshudov, and M. Z. Papiz. 2003. Macromolecular TLS refinement in REFMAC at moderate resolutions. Methods Enzymol. 374:300-321.